Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct. 03, 2022 12:44 PM ETBelite Bio, Inc (BLTE)By: Jonathan Block, SA News Editor2 Comments

Girl Suffer From Eye Irritation

patpitchaya/iStock via Getty Images

  • Belite Bio (NASDAQ:BLTE) is off 21% in Monday trading after reporting disappointing phase 2 results on tinlarebant for adolescent Stargardt Disease, a rare eye disease characterized by fatty material build-up in the macula.
  • While the company presented the

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.